Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer: The NEfERT-T Randomized Clinical Trial.
Abstract | IMPORTANCE: Efficacious ERBB2 (formerly HER2 or HER2/neu)-directed treatments, in addition to trastuzumab and lapatinib, are needed. OBJECTIVE: DESIGN, SETTING, AND PARTICIPANTS: In the randomized, controlled, open-label NEfERT-T trial conducted from August 2009 to December 2014 at 188 centers in 34 countries in Europe, Asia, Africa, and North America, 479 women with previously untreated recurrent and/or metastatic ERBB2-positive breast cancer were randomized to 1 of 2 treatment arms ( neratinib- paclitaxel [n = 242] or trastuzumab- paclitaxel [n = 237]). Women with asymptomatic central nervous system metastases were eligible, and randomization was stratified by prior trastuzumab and lapatinib exposure, hormone-receptor status, and region. INTERVENTIONS: Women received neratinib (240 mg/d orally) or trastuzumab (4 mg/kg then 2 mg/kg weekly), each combined with paclitaxel (80 mg/m2 on days 1, 8, and 15 every 28 days). Primary prophylaxis for diarrhea was not mandatory. MAIN OUTCOME AND MEASURES: The primary outcome was progression-free survival. Secondary end points were response rate, clinical benefit rate, duration of response, frequency, and time to symptomatic and/or progressive central nervous system lesions, and safety. RESULTS: The intent-to-treat population comprised 479 women 18 years or older ( neratinib- paclitaxel, n = 242; trastuzumab- paclitaxel, n = 237) randomized and stratified in their respective treatment arms by prior trastuzumab and lapatinib exposure, hormone-receptor status, and region. Median progression-free survival was 12.9 months (95% CI, 11.1-14.9) with neratinib- paclitaxel and 12.9 months (95% CI, 11.1-14.8) with trastuzumab- paclitaxel (hazard ratio [HR], 1.02; 95% CI, 0.81-1.27; P =.89). With neratinib- paclitaxel, the incidence of central nervous system recurrences was lower (relative risk, 0.48; 95% CI, 0.29-0.79; P = .002) and time to central nervous system metastases delayed (HR, 0.45; 95% CI, 0.26-0.78; P = .004). Common grade 3 to 4 adverse events were diarrhea (73 of 240 patients [30.4%] with neratinib- paclitaxel and 9 of 234 patients [3.8%] with trastuzumab- paclitaxel), neutropenia (31 patients [12.9%] vs 34 patients [14.5%]) and leukopenia (19 patients [7.9%] vs 25 patients [10.7%]); no grade 4 diarrhea was observed. CONCLUSIONS AND RELEVANCE: TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00915018.
|
Authors | Ahmad Awada, Ramon Colomer, Kenichi Inoue, Igor Bondarenko, Rajendra A Badwe, Georgia Demetriou, Soo-Chin Lee, Ajay O Mehta, Sung-Bae Kim, Thomas Bachelot, Chanchal Goswami, Suryanarayan Deo, Ron Bose, Alvin Wong, Feng Xu, Bin Yao, Richard Bryce, Lisa A Carey |
Journal | JAMA oncology
(JAMA Oncol)
Vol. 2
Issue 12
Pg. 1557-1564
(Dec 01 2016)
ISSN: 2374-2445 [Electronic] United States |
PMID | 27078022
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Quinolines
- ERBB2 protein, human
- Receptor, ErbB-2
- neratinib
- Trastuzumab
- Paclitaxel
|
Topics |
- Adolescent
- Adult
- Aged
- Antineoplastic Combined Chemotherapy Protocols
(administration & dosage, adverse effects)
- Breast Neoplasms
(drug therapy, genetics, pathology)
- Central Nervous System Neoplasms
(drug therapy, genetics, pathology, secondary)
- Disease-Free Survival
- Drug-Related Side Effects and Adverse Reactions
(pathology)
- Female
- Humans
- Kaplan-Meier Estimate
- Middle Aged
- Paclitaxel
(administration & dosage, adverse effects)
- Quinolines
(administration & dosage, adverse effects)
- Receptor, ErbB-2
(genetics)
- Trastuzumab
(administration & dosage, adverse effects)
|
|
Join CureHunter, for free Research Interface BASIC access!
Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease.
Find out why thousands of doctors, pharma researchers and patient activists
around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!
|